Today, Pfizer Inc. announced that US health regulators approved the first drug to treat a rare, progressive lung disease.
The company said that the US Food and Drug Administration (FDA) approved its Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system.
The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.
An experimental antibody therapy has shown promise in suppressing HIV infection, bringing optimism to the HIV field and suggesting new strategies for fighting or even preventing HIV.
Rockefeller University researchers have found that an experimental therapy, part of a new generation of so-called broadly neutralizing antibodies, can dramatically reduce the amount of virus present in a patient’s blood. The study was published this week in Nature.
Dell Inc. has extended its partnership with Translational Genomics Research Institute (TGen) to assist reasearchers and physicians expand the impact and reach of precision medicine efforts for pediatric cancer.
Not every cancer is curable. The patient, may sometimes need to “live with it’, as is the case with diabetes or heart diseases. Controlling, rather than curing is the best course ahead for certain types of cancers including ovarian, chronic leukemia, some lymphomas, and metastatic breast and prostate cancers. Controlling cancer implies to limit the spreading. The cancer may shrink, but nevertheless it will be there.